Fosamprenavir Expanded Access

• Status: Completed
• Trial end date: 2005-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This open-label study will enable HIV-infected adults with limited treatment options to receive fosamprenavir until commercial supplies are available in Switzerland.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: GlaxoSmithKline
• Treatments: Fosamprenavir

Criteria

Inclusion Criteria:

• HIV-1 infected subjects.

• Subjects must belong to one of the following populations:

1. Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.

2. Subjects who already receive amprenavir (Agenerase®)

3. Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.